As with other industries, information is the substrate of Life Sciences, yet the Life Sciences have been slower to adopt information technology than other industries. Aircraft manufactures have been "virtually" test flying aircraft for decades now. The financial industry has been working with electronic regulatory submissions for about the same amount of time. But we are at a new age of life sciences, a period where discovery through bedside will be enhanced through the use of information technology.
The greater adoption of IT in Life Sciences is being driven not only through the clear benefits in quality and efficiency that we can all understand, but through market pressures and changes in the life sciences industry. Fewer blockbuster drugs and a higher failure rate in the discovery process; pharmacogenomics requires management of an ever increasing number of products in the portfolio; greater regulatory pressure; global development; biosimilar, biogeneric and generic pharmaceuticals are all affecting the way pharmaceutical and biotechnology companies operate. The response to this market pressure is a more efficient and effective industry — lead by information technology.
The true power of IT systems is first realized as the data flows freely from one system to the other and, as Life Sciences companies automate more processes internally, integration will lead to increased efficiency and quality.
For More Information Please us the weblink: The Flow of Data from Bench to Bedside: Finally Enabled by Electronic Submission.
No comments:
Post a Comment